Piper Sandler raised the firm’s price target on NeoGenomics (NEO) to $13 from $12 following quarterly results. The firm keeps an Overweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics Faces High-Stakes Risk as Test Reliability and Diagnostic Errors Threaten Reputation and Legal Exposure
- NeoGenomics Earnings Call Signals Growth With Caveats
- NeoGenomics: Solid Core Growth, Aligned 2026 Outlook, and RaDaR Expansion Support Buy Rating and Higher Price Target
- Midday Fly By: Warner Bros. reopens Paramount talks
- NeoGenomics sees FY26 adjusted EPS 16c-21c, consensus 19c